Drug Profile

TERN 201

Alternative Names: SSAO inhibitors - Merck & Co; TERN-201

Latest Information Update: 11 May 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Eli Lilly and Company
Developer Merck & Co
Class Antineoplastics; Hepatoprotectants; Small molecules
Mechanism of Action AOC3 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Solid tumours
No development reported Non-alcoholic steatohepatitis

Most Recent Events

05 May 2026 Terns Pharmaceuticals has been acquired and merged into Merck & Co
28 Aug 2024 No recent reports of development identified for phase-I development in Non-alcoholic-steatohepatitis in USA (PO)
01 Mar 2023 TERN 201 is available for licensing as of 01 Mar 2023. https://www.ternspharma.com/ 3781244

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com